Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023
2023年5月9日 - 2:02PM
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting
on June 21, 2023
Vivoryon Therapeutics
N.V. to Hold its 2023 Annual General
Meeting on June 21, 2023
Halle (Saale) / Munich,
Germany, May 9, 2023 –
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)
(Vivoryon), a clinical stage company focused on
the discovery and development of small molecule medicines to
modulate the activity and stability of pathologically altered
proteins, today announced that its 2023 Annual General Meeting will
be held on Wednesday, June 21, 2023, at 1:00 p.m. (CEST).
Shareholders can follow the AGM virtually via audio webcast on the
Company’s website
(https://www.vivoryon.com/annual-general-meeting-2023/), or attend
in person at Sheraton Amsterdam Airport Hotel, Schiphol Boulevard
101, Amsterdam 1118BG, The Netherlands.
The full agenda and all relevant documents are
available on the Company’s website.
Reflecting Vivoryon’s continued progress towards
becoming a late-stage clinical development company and in line with
the Company’s commitment to meeting international best-practice
standards for corporate governance and diversity, the agenda
includes, among other items, the appointment of two new members to
Vivoryon’s Non-Executive Board of Directors. The proposed
appointments follow the decision of the two long-standing members
Dinnies Johannes von der Osten, PhD, and Jörg Neermann, PhD,
to step down at the 2023 Annual General Meeting, as announced on
May 1, 2023.
- Appointment of Kugan
Sathiyanandarajah as Non-Executive Director to Vivoryon’s Board of
Directors:
Kugan Sathiyanandarajah joined Kohlberg Kravis
Roberts & Co. L.P. (KKR), a leading global investment firm, in
2010. As Managing Director, Private Equity, he is Head of KKR's
Health Care Strategic Growth business in Europe. Mr.
Sathiyanandarajah is a member of the Health Care industry team and
was based in KKR’s Menlo Park (California, U.S.) office from
2019 to 2020. He has played a significant role in a
number of KKR’s investments across growth equity and private equity
in both Europe and the U.S., including Gamma Biosciences, Argenta,
Nordic Bioscience, Biosynth Carbosynth, Alliance Pharma, LGC Group,
Walgreens Boots Alliance, Alvogen and Galenica. He currently serves
on the board of directors of Gamma Biosciences, Argenta, Nordic
Bioscience, Biosynth Carbosynth and EchoNous. Prior to joining KKR,
he was with Goldman Sachs, where he was a member of the UK mergers
and acquisitions team. Mr. Sathiyanandarajah earned an M.A. (First
Class Hons) in Physical Natural Sciences (Chemistry) from the
University of Cambridge, UK.
- Appointment of Professor
Morten Asser Karsdal as Non-Executive Director to Vivoryon’s Board
of Directors:
Professor Dr. Morten Asser Karsdal, MSc, PhD,
mMBA, joined Nordic Bioscience in 2001 and rose to become CEO in
2010. He serves as Adjunct Professor, Molecular Medicine at the
Southern University of Denmark. Professor Karsdal has extensive
research, pharmacological and biomarker experience in the field of
rheumatology (rheumatoid arthritis, osteoarthritis), diabetes and
fibrosis with more than 625 peer-reviewed publications in top
journals. Professor Karsdal has spearheaded the development of FDA
approved molecular diagnostics and commercialized more than 125
ELISA assays. Utilizing his broad experience in clinical trial
design, clinical use of biochemical markers, and the use of
biomarkers in translational science, Professor Karsdal has
participated in more than 100 clinical studies, and two
pivotal phase 3 clinical studies in osteoarthritis. Professor
Karsdal has worked with multiple oral formulations of smaller
proteins and has identified and participated in the development of
treatments for fibrosis, osteoporosis, osteoarthritis and diabetes,
from target identification, preclinical development through phase 1
to phase 3 studies.
###
About Vivoryon Therapeutics
N.V.Vivoryon is a clinical stage biotechnology company
focused on developing innovative small molecule-based medicines.
Driven by our passion for ground-breaking science and innovation,
we strive to change the lives of patients in need suffering from
severe diseases. We leverage our in-depth expertise in
understanding post-translational modifications to develop medicines
that modulate the activity and stability of proteins which are
altered in disease settings. Beyond our lead program,
varoglutamstat, which is in Phase 2 clinical development to treat
Alzheimer’s disease, we have established a solid pipeline of orally
available small molecule inhibitors for various indications
including cancer, inflammatory diseases and fibrosis.
www.vivoryon.com
Vivoryon Forward Looking
StatementsThis press release includes forward-looking
statements, including, without limitation, those regarding the
business strategy, management plans and objectives for future
operations of the Vivoryon Therapeutics N.V. (the “Company”),
estimates and projections with respect to the market for the
Company’s products and forecasts and statements as to when the
Company’s products may be available. Words such as “anticipate,”
“believe,” “estimate,” “expect,” “forecast,” “intend,” “may,”
“plan,” “project,” “predict,” “should” and “will” and similar
expressions as they relate to the Company are intended to identify
such forward-looking statements. These forward-looking statements
are not guarantees of future performance; rather they are based on
the Management’s current expectations and assumptions about future
events and trends, the economy and other future conditions. The
forward-looking statements involve a number of known and unknown
risks and uncertainties. These risks and uncertainties and other
factors could materially adversely affect the outcome and financial
effects of the plans and events described herein. Actual results,
performance or events may differ materially from those expressed or
implied in such forward-looking statements and from expectations.
As a result, no undue reliance should be placed on such
forward-looking statements. This press release does not contain
risk factors. Certain risk factors that may affect the Company’s
future financial results are discussed in the published annual
financial statements of the Company. This press release, including
any forward-looking statements, speaks only as of the date of this
press release. The Company does not assume any obligation to update
any information or forward-looking statements contained herein,
save for any information required to be disclosed by law.
For more information, please contact:
Investor ContactStern IRJulie SeidelTel: +1
212-698-8684Email: SternIR-Vivoryon@sternir.com
Media ContactTrophic CommunicationsValeria
FisherTel: +49 175 8041816Email: vivoryon@trophic.eu
- 230509_Notice_AGM Convocation
Vivoryon Therapeut (EU:VVY)
過去 株価チャート
から 4 2024 まで 5 2024
Vivoryon Therapeut (EU:VVY)
過去 株価チャート
から 5 2023 まで 5 2024